205 related articles for article (PubMed ID: 25904246)
1. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.
Villa NY; Wasserfall CH; Meacham AM; Wise E; Chan W; Wingard JR; McFadden G; Cogle CR
Blood; 2015 Jun; 125(24):3778-88. PubMed ID: 25904246
[TBL] [Abstract][Full Text] [Related]
2. Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.
Villa NY; Rahman MM; McFadden G; Cogle CR
Viruses; 2016 Mar; 8(3):85. PubMed ID: 27011200
[TBL] [Abstract][Full Text] [Related]
3. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
Villa NY; Bais S; Chan WM; Meacham AM; Wise E; Rahman MM; Moreb JS; Rosenau EH; Wingard JR; McFadden G; Cogle CR
Cytotherapy; 2016 Mar; 18(3):465-80. PubMed ID: 26857235
[TBL] [Abstract][Full Text] [Related]
5. Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.
Villa NY; McFadden G
Curr Pathobiol Rep; 2018; 6(4):247-263. PubMed ID: 30595970
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Madlambayan GJ; Bartee E; Kim M; Rahman MM; Meacham A; Scott EW; McFadden G; Cogle CR
Leuk Res; 2012 May; 36(5):619-24. PubMed ID: 22341701
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic myxoma virus: the path to clinic.
Chan WM; Rahman MM; McFadden G
Vaccine; 2013 Sep; 31(39):4252-8. PubMed ID: 23726825
[TBL] [Abstract][Full Text] [Related]
8. Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.
Bartee E; Meacham A; Wise E; Cogle CR; McFadden G
PLoS One; 2012; 7(8):e43298. PubMed ID: 22905251
[TBL] [Abstract][Full Text] [Related]
9. Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer.
Villa NY; Franco LS; McFadden G
Methods Mol Biol; 2020; 2058():95-110. PubMed ID: 31486033
[TBL] [Abstract][Full Text] [Related]
10. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.
Ogbomo H; Zemp FJ; Lun X; Zhang J; Stack D; Rahman MM; McFadden G; Mody CH; Forsyth PA
PLoS One; 2013; 8(6):e66825. PubMed ID: 23762498
[TBL] [Abstract][Full Text] [Related]
11. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
[TBL] [Abstract][Full Text] [Related]
12. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
[TBL] [Abstract][Full Text] [Related]
13. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.
Bartee E; Chan WM; Moreb JS; Cogle CR; McFadden G
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1540-51. PubMed ID: 22516053
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
Lilly CL; Villa NY; Lemos de Matos A; Ali HM; Dhillon JS; Hofland T; Rahman MM; Chan W; Bogen B; Cogle C; McFadden G
Mol Ther Oncolytics; 2017 Mar; 4():31-40. PubMed ID: 28345022
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
Binsfeld M; Beguin Y; Belle L; Otjacques E; Hannon M; Briquet A; Heusschen R; Drion P; Zilberberg J; Bogen B; Baron F; Caers J
PLoS One; 2014; 9(11):e113764. PubMed ID: 25415267
[TBL] [Abstract][Full Text] [Related]
17. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
19. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
20. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
